Free Trial

Burney Co. Sells 22,279 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Supernus Pharmaceuticals logo with Medical background

Burney Co. trimmed its holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 26.8% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 60,873 shares of the specialty pharmaceutical company's stock after selling 22,279 shares during the period. Burney Co. owned about 0.11% of Supernus Pharmaceuticals worth $1,994,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently made changes to their positions in the company. Vanguard Group Inc. lifted its position in shares of Supernus Pharmaceuticals by 0.4% during the fourth quarter. Vanguard Group Inc. now owns 6,150,759 shares of the specialty pharmaceutical company's stock valued at $222,411,000 after purchasing an additional 22,852 shares in the last quarter. Geode Capital Management LLC increased its holdings in Supernus Pharmaceuticals by 1.9% during the fourth quarter. Geode Capital Management LLC now owns 1,510,568 shares of the specialty pharmaceutical company's stock worth $54,633,000 after buying an additional 28,517 shares during the last quarter. GW&K Investment Management LLC increased its holdings in Supernus Pharmaceuticals by 14.6% during the first quarter. GW&K Investment Management LLC now owns 1,382,441 shares of the specialty pharmaceutical company's stock worth $45,275,000 after buying an additional 176,091 shares during the last quarter. American Century Companies Inc. increased its stake in shares of Supernus Pharmaceuticals by 9.2% in the fourth quarter. American Century Companies Inc. now owns 1,140,705 shares of the specialty pharmaceutical company's stock worth $41,248,000 after purchasing an additional 95,777 shares in the last quarter. Finally, Northern Trust Corp increased its stake in shares of Supernus Pharmaceuticals by 18.3% in the fourth quarter. Northern Trust Corp now owns 717,161 shares of the specialty pharmaceutical company's stock worth $25,933,000 after purchasing an additional 110,867 shares in the last quarter.

Analysts Set New Price Targets

Separately, Wall Street Zen downgraded shares of Supernus Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Sunday.

Check Out Our Latest Stock Analysis on Supernus Pharmaceuticals

Supernus Pharmaceuticals Stock Down 0.4%

NASDAQ:SUPN traded down $0.12 during mid-day trading on Thursday, hitting $32.85. 540,341 shares of the stock traded hands, compared to its average volume of 698,889. The business's 50-day moving average price is $32.48 and its 200 day moving average price is $33.55. The company has a market cap of $1.84 billion, a PE ratio of 29.59 and a beta of 0.70. Supernus Pharmaceuticals, Inc. has a 12-month low of $27.05 and a 12-month high of $40.28.

About Supernus Pharmaceuticals

(Free Report)

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.

Read More

Institutional Ownership by Quarter for Supernus Pharmaceuticals (NASDAQ:SUPN)

Should You Invest $1,000 in Supernus Pharmaceuticals Right Now?

Before you consider Supernus Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Supernus Pharmaceuticals wasn't on the list.

While Supernus Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Joby vs. Archer: The $10 Billion eVTOL Battle
3 Small-Cap Biotech Stocks With Catalysts Too Big to Ignore
AI Stocks Are Printing Money — These 3 Are Just Getting Started

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines